What is the clinical evidence from this study?

Study design: Observational. Population: Dedifferentiated liposarcoma (DDLPS) (n=123). Intervention: Dedifferentiated liposarcoma. Primary outcome: Real-world overall survival (rwOS) from diagnosis and from the start of the first systemic therapy after documented metastatic disease.

June 12, 2026Cancer MedicineOpen Access

Patients with dedifferentiated liposarcoma treated in US community settings had a median real-world overall survival of 44.2 months from diagnosis.

View Full Paper

Ask AI

Bookmark

Why the study?

What are the real-world patterns of diagnosis, clinical management, and outcomes of patients with dedifferentiated liposarcoma in US community settings?

Population

123 patients diagnosed with dedifferentiated liposarcoma between January 1, 2008, and October 31, 2023…

Design

Cohort

Key result

Patients with dedifferentiated liposarcoma treated in US community settings had a median real-world overall survival of 44.2 months from diagnosis.

Authors

JBJames E. Butrynski BNBal Nepal CHChenxiao Hu

Discussion

Member takes

Overview

Offers cautionary real-world DDLPS survival context; leaves open optimal therapy sequencing pending prospective trials.

Key Points

To evaluate clinical characteristics and real-world outcomes of patients with dedifferentiated liposarcoma treated in US community oncology centers.
Retrospective observational study using electronic health records (EHRs) from January 1, 2008, to October 31, 2023.
Included 123 patients diagnosed with dedifferentiated liposarcoma.
Primary outcomes included real-world overall survival (rwOS) and progression-free survival (rwPFS).
Median overall survival (rwOS) was 44.2 months.
For patients with metastatic disease, median progression-free survival (rwPFS) was 2.7 months.
Overall survival from the start of first-line systemic therapy was 11.7 months.

Study Design

Type

Observational (n=123)

Multicenter

Yes

Structured PICO

What are the real-world patterns of diagnosis, clinical management, and outcomes of patients with dedifferentiated liposarcoma in US community settings?

Population

123 patients (33.3% women) diagnosed with dedifferentiated liposarcoma in US community settings between 2008 and 2023.

Exposure

Real-world clinical management including surgery, radiation therapy, and systemic agents (particularly first-line anthracycline)

Outcome

Real-world overall survival (rwOS) from diagnosis and from the start of the first systemic therapy after documented metastatic disease (1L[M]) until death (due to any cause)hard clinical

Patients with dedifferentiated liposarcoma treated in US community settings have relatively poor survival rates, highlighting an unmet need for better therapeutics.

Cite This Study

Butrynski et al. (2026) conducted an observational in Dedifferentiated liposarcoma (DDLPS) (n=123). Dedifferentiated liposarcoma was evaluated on Real-world overall survival (rwOS) from diagnosis and from the start of the first systemic therapy after documented metastatic disease. Patients with dedifferentiated liposarcoma treated in US community settings had a median real-world overall survival of 44.2 months from diagnosis.

synapsesocial.com/papers/6a2bd1056550ea4541ffe860 https://doi.org/10.1002/cam4.71914

View Full Paper

Ask AI

Bookmark

June 12, 2026Cancer MedicineOpen Access

Patients with dedifferentiated liposarcoma treated in US community settings had a median real-world overall survival of 44.2 months from diagnosis.

View Full Paper

Ask AI

Bookmark

Why the study?

What are the real-world patterns of diagnosis, clinical management, and outcomes of patients with dedifferentiated liposarcoma in US community settings?

Population

123 patients diagnosed with dedifferentiated liposarcoma between January 1, 2008, and October 31, 2023…

Design

Cohort

Key result

Patients with dedifferentiated liposarcoma treated in US community settings had a median real-world overall survival of 44.2 months from diagnosis.

Authors

JBJames E. Butrynski BNBal Nepal CHChenxiao Hu

Discussion

Member takes

Overview

Offers cautionary real-world DDLPS survival context; leaves open optimal therapy sequencing pending prospective trials.

Key Points

To evaluate clinical characteristics and real-world outcomes of patients with dedifferentiated liposarcoma treated in US community oncology centers.
Retrospective observational study using electronic health records (EHRs) from January 1, 2008, to October 31, 2023.
Included 123 patients diagnosed with dedifferentiated liposarcoma.
Primary outcomes included real-world overall survival (rwOS) and progression-free survival (rwPFS).
Median overall survival (rwOS) was 44.2 months.
For patients with metastatic disease, median progression-free survival (rwPFS) was 2.7 months.
Overall survival from the start of first-line systemic therapy was 11.7 months.

Study Design

Type

Observational (n=123)

Multicenter

Yes

Structured PICO

What are the real-world patterns of diagnosis, clinical management, and outcomes of patients with dedifferentiated liposarcoma in US community settings?

Population

123 patients (33.3% women) diagnosed with dedifferentiated liposarcoma in US community settings between 2008 and 2023.

Exposure

Real-world clinical management including surgery, radiation therapy, and systemic agents (particularly first-line anthracycline)

Outcome

Real-world overall survival (rwOS) from diagnosis and from the start of the first systemic therapy after documented metastatic disease (1L[M]) until death (due to any cause)hard clinical

Patients with dedifferentiated liposarcoma treated in US community settings have relatively poor survival rates, highlighting an unmet need for better therapeutics.

Cite This Study

synapsesocial.com/papers/6a2bd1056550ea4541ffe860 https://doi.org/10.1002/cam4.71914

View Full Paper

Ask AI

Bookmark